Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
1998-01-12
2001-01-09
Killos, Paul J. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S349000, C514S350000, C514S354000, C514S365000, C546S298000, C548S147000, C548S184000, C562S427000, C562S490000
Reexamination Certificate
active
06172115
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to a method for preventing onset or recurrence of restenosis after angioplasty procedures by administering an RXR-specific agonist retinoid alone or in combination with a PPAR&ggr; ligand, thereby inhibiting proliferation of vascular smooth muscle cells.
BACKGROUND OF THE INVENTION
Approximately 30-40% of atherosclerotic coronary arteries treated by angioplasty or by bypass surgery occlude as a result of restenosis. Vascular smooth muscle cell (VSMC) proliferation and migration are critical events in the development of restenosis and in the progression of atherosclerosis.
Percutaneous transluminal angioplasty (PTA), defined as any percutaneous transluminal method of decreasing stenosis within a blood vessel, whether caused by the existence of an atheromatous plaque, thrombosis, embolus, and/or mineral deposit, by any of a number of means such as balloon dilation, thermal ablation, laser atherectomy, mechanical shaving, extraction or ultrasonic pulverization, hereinafter referred to as angioplasty, is widely used in the treatment of occlusive vascular disease. However, it has been found that restenosis frequently occurs, and in the case of coronary angioplasty, restenosis occurs in about a third of cases within 6 months of the procedure.
Angiotensin converting enzyme (ACE) inhibitors or the physiologically tolerable salts thereof have been used in the treatment of atherosclerosis, thrombosis and/or peripheral vascular disease in mammals. It has been disclosed that, because ACE is predominantly localized in the luminal plasma membrane of the endothelial cell, ACE inhibitors can interfere in platelet-endothelium interaction. In addition, ACE inhibition potentiates the action of bradykinin (a strong stimulator of prostacyclin release from endothelial cells) by inhibiting its degradation. ACE inhibitors, consequently, have an inhibitory effect on platelet aggregation (See U.S. Pat. Nos. 5,140,012 and 5,166,143). In large scale clinical trials, ACE inhibitors have failed to demonstrate a beneficial effect in preventing restenosis following angioplasty.
Other methods for preventing restenosis after angioplasty include combining photoactivatable psoralen and ultraviolet radiation, as set forth in U.S. Pat. No. 5,116,864, and radiation from a source of radioactivity, as set forth in U.S. Pat. No. 5,213,561.
Recently, a gene has been discovered, that is present in certain families resident in Limone, Italy, which codes for a protein that may have the function of preventing the build-up of fatty deposits that clog the arteries and may be especially effective in preventing the reclogging of arteries that occurs after a blocked vessel has been cleared with balloon angioplasty surgery.
A commonly assigned, co-pending application, U.S. Ser. No. 08/794,289, describes methods of using RAR-selective retinoids and retinoid pan-agonists in treating restenosis.
A commonly assigned, co-pending application, U.S. Ser. No. 08/466,000, of Chandraratna, et al. describes 2,4-pentanedioic acid derivatives which have RXR-retinoid activity. Additionally, published PCT application 97/12853 discloses a variety of compounds which are dimer-selective RXR modulators.
Further, commonly assigned U.S. Pat. No. 5,455,265 and a divisional application pending therefrom describes and claims methods of treatment with certain compounds having selective agonist-like activity on RXR retinoid receptors.
Published PCT application 96/33724 discloses ligands that bind to and modulate the processes mediated by peroxisome proliferator activated receptor—gamma (PPAR&ggr;).
The above-mentioned patents and pending patent applications are incorporated herein by reference in their entirety. The portion of commonly assigned U.S. Pat. No. 5,455,265 to Chandraratna which details assays which are known and used in the art to measure RXR agonist activity and are described from column 5, line 37 through column 11, line 58 is specifically and expressly incorporated herein by reference.
To date, none of the present methods for preventing restenosis are suitable in every aspect. Therefore, the search for methods for preventing the onset of restenosis after angioplasty continues.
SUMMARY OF THE INVENTION
It has been discovered in accordance with the present invention that retinoid-like compounds which act selectively and preferably even specifically as agonists of the RXR receptor sites in preference to the RAR receptor sites, possess desirable therapeutic properties associated with retinoids, but without having one or more undesirable side effects of retinoids, such as teratogenicity or skin toxicity. For the purposes of the present invention, a compound is defined to be a specific or at least selective agonist of the RXR receptor site if the compound is at least approximately ten times more potent as an agonist at RXR receptor sites than at the RAR receptor sites.
Accordingly the present invention relates to methods of treating animals of the mammalian species, including humans, for preventing or reducing the occurrence of restenosis following any of the medically accepted angioplasty procedures with non-teratogenic compositions containing: 1) an RXR-specific agonist compound as defined above; 2) a combination of an RXR-specific agonist compound as defined above and a PPAR&ggr;-selective prostaglandin or prostaglandin-like compound including synthetic analogs such as the thiazolidinediones.
The present invention is also directed to the pharmaceutical compositions used in the above-noted methods of treatment.
REFERENCES:
patent: 4096341 (1978-06-01), Frazer
patent: 4326055 (1982-04-01), Loeliger
patent: 4391731 (1983-07-01), Boller et al.
patent: 4695649 (1987-09-01), Magami et al.
patent: 4723028 (1988-02-01), Shudo
patent: 4739098 (1988-04-01), Chandraratna
patent: 4740519 (1988-04-01), Shroot et al.
patent: 4808597 (1989-02-01), Hoffman et al.
patent: 4810804 (1989-03-01), Chandraratna
patent: 4826969 (1989-05-01), Maignan et al.
patent: 4826984 (1989-05-01), Berlin et al.
patent: 4855320 (1989-08-01), Chatterjee et al.
patent: 4876349 (1989-10-01), Klaus et al.
patent: 4895868 (1990-01-01), Chandraratna
patent: 4923384 (1990-05-01), Chandraratna
patent: 4927947 (1990-05-01), Chandraratna
patent: 4931458 (1990-06-01), Chandraratna
patent: 4980369 (1990-12-01), Chandraratna
patent: 4992468 (1991-02-01), Chandraratna
patent: 5006550 (1991-04-01), Chandraratna
patent: 5013744 (1991-05-01), Chandraratna
patent: 5015658 (1991-05-01), Chandraratna
patent: 5023341 (1991-06-01), Chandraratna
patent: 5037825 (1991-08-01), Klaus et al.
patent: 5045551 (1991-09-01), Chandraratna
patent: 5053523 (1991-10-01), Chandraratna
patent: 5068525 (1991-11-01), Chandraratna
patent: 5089509 (1992-02-01), Chandraratna
patent: 5130335 (1992-07-01), Chandraratna
patent: 5134159 (1992-07-01), Chandraratna
patent: 5162546 (1992-11-01), Chandraratna
patent: 5175185 (1992-12-01), Chandraratna
patent: 5183827 (1993-02-01), Chandraratna
patent: 5202471 (1993-04-01), Chandraratna
patent: 5231113 (1993-07-01), Chandraratna
patent: 5234926 (1993-08-01), Chandraratna
patent: 5248777 (1993-09-01), Chandraratna
patent: 5264456 (1993-11-01), Chandraratna
patent: 5264578 (1993-11-01), Chandraratna
patent: 5272156 (1993-12-01), Chandraratna
patent: 5278318 (1994-01-01), Chandraratna
patent: 5324744 (1994-06-01), Chandraratna
patent: 5324840 (1994-06-01), Chandraratna
patent: 5326898 (1994-07-01), Chandraratna
patent: 5344949 (1994-09-01), Chandraratna
patent: 5346895 (1994-09-01), Chandraratna
patent: 5346915 (1994-09-01), Chandraratna
patent: 5348972 (1994-09-01), Chandraratna
patent: 5348975 (1994-09-01), Chandraratna
patent: 5349105 (1994-09-01), Chandraratna
patent: 5354752 (1994-10-01), Chandraratna
patent: 5380877 (1995-01-01), Chandraratna
patent: 5391753 (1995-02-01), Chandraratna
patent: 5399561 (1995-03-01), Chandraratna
patent: 5399586 (1995-03-01), Davis et al.
patent: 5407937 (1995-04-01), Chandraratna
patent: 5414007 (1995-05-01), Chandraratna
patent: 5426118 (1995-06-01), Chandraratna
patent: 3316932 (1983-11-
Allergan Sales Inc.
Baran Robert J.
Fischer Carlos A.
Killos Paul J.
Voet Martin A.
LandOfFree
Method for preventing onset of restenosis after angioplasty... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for preventing onset of restenosis after angioplasty..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for preventing onset of restenosis after angioplasty... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2474750